Using 3,301 cases and 3,786 controls from 14 studies, we showed reduced urinary cancer risk in patients having CYP2E1 RsaI/PstI c1c2 + c2c2 genotype (OR = 0.73, 95% CI = 0.68–0.79, P < 0.001), comparing with the subjects carrying wide-type homozygous c1c1 genotype. Here, CYP2E1 is linked to cancer.